DIO Resultados de beneficios anteriores

Pasado controles de criterios 2/6

DIOhan disminuido a un ritmo medio anual de -27.2%, mientras que en la industria Medical Equipment los ingresos han sido de growing a 16.7% anuales. Los ingresos han sido growing a un ritmo medio de 8.1% al año. DIO La rentabilidad de los fondos propios de la empresa es de 1.3% y sus márgenes netos son de 2.1%.

Información clave

-27.2%

Tasa de crecimiento de los beneficios

-27.3%

Tasa de crecimiento del BPA

Crecimiento de la industria Medical Equipment	22.7%
Tasa de crecimiento de los ingresos	8.1%
Rentabilidad financiera	1.3%
Margen neto	2.1%
Última actualización de beneficios	31 Dec 2023

Actualizaciones de resultados anteriores recientes

Recent updates

We Think DIO (KOSDAQ:039840) Can Stay On Top Of Its Debt

May 03

An Intrinsic Calculation For DIO Corporation (KOSDAQ:039840) Suggests It's 43% Undervalued

Mar 18

What Type Of Shareholders Make Up DIO Corporation's (KOSDAQ:039840) Share Registry?

Mar 05

How Much Did DIO's(KOSDAQ:039840) Shareholders Earn From Share Price Movements Over The Last Year?

Jan 09

Is DIO Corporation's (KOSDAQ:039840) Stock Price Struggling As A Result Of Its Mixed Financials?

Dec 27

Should You Use DIO's (KOSDAQ:039840) Statutory Earnings To Analyse It?

Dec 09

Do Institutions Own DIO Corporation (KOSDAQ:039840) Shares?

Nov 27

Desglose de ingresos y gastos
Beta

Cómo gana y gasta dinero DIO. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).

Historial de beneficios e ingresos

KOSDAQ:A039840 Ingresos, gastos y beneficios (KRW Millions)
Fecha	Ingresos	Beneficios	Gastos G+A	Gastos de I+D
31 Dec 23	155,818	3,311	78,223	3,834
30 Sep 23	149,128	-8,619	79,215	3,737
30 Jun 23	147,233	-10,529	81,700	3,975
31 Mar 23	137,948	-11,486	81,592	4,008
31 Dec 22	131,306	-20,458	81,155	3,898
30 Sep 22	146,583	7,784	76,924	3,421
30 Jun 22	147,461	15,121	70,113	3,270
31 Mar 22	150,618	20,377	65,252	3,046
31 Dec 21	150,037	28,255	62,008	2,780
30 Sep 21	146,007	25,733	53,943	2,605
30 Jun 21	135,782	20,255	48,767	2,276
31 Mar 21	123,976	16,222	45,120	2,135
31 Dec 20	120,056	11,153	44,900	1,980
30 Sep 20	121,120	10,047	50,748	2,368
30 Jun 20	123,795	14,227	52,610	2,480
31 Mar 20	128,284	20,348	54,140	2,509
31 Dec 19	127,165	21,732	53,074	2,827
30 Sep 19	111,987	16,856	53,710	3,448
30 Jun 19	103,759	12,087	51,808	3,296
31 Mar 19	95,823	5,043	48,913	3,384
31 Dec 18	91,043	5,455	46,951	2,820
30 Sep 18	92,510	6,233	38,416	2,454
30 Jun 18	93,946	9,320	37,257	1,928
31 Mar 18	95,257	13,286	36,858	2,436
31 Dec 17	91,918	8,559	34,728	2,570
30 Sep 17	88,201	19,935	34,896	2,542
30 Jun 17	87,651	18,839	33,242	2,514
31 Mar 17	87,133	19,480	29,330	2,310
31 Dec 16	88,020	20,514	26,738	2,228
30 Sep 16	90,638	17,526	22,418	2,012
30 Jun 16	84,794	16,672	19,843	2,012
31 Mar 16	78,580	11,523	18,447	1,678
31 Dec 15	71,939	9,252	17,584	1,581
30 Sep 15	65,964	8,223	18,009	1,090
30 Jun 15	64,052	3,939	20,943	1,090
31 Mar 15	60,988	-2,036	24,273	1,377
31 Dec 14	61,576	-3,610	26,786	1,441
30 Sep 14	65,834	-11,429	34,153	1,530
30 Jun 14	65,058	-12,642	33,062	1,530
31 Mar 14	65,768	-8,819	31,164	1,713
31 Dec 13	62,795	-8,271	29,435	1,961
30 Sep 13	52,910	-8,012	25,467	2,010
30 Jun 13	48,992	-6,654	23,809	2,010

Ingresos de calidad: A039840 tiene ganancias de alta calidad.

Margen de beneficios creciente: A039840 fueron rentables en el pasado.

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: A039840Los beneficios de la empresa han disminuido en 27.2% al año en los últimos 5 años.

Acelerando crecimiento: A039840 ha pasado a ser rentable en el último año, lo que dificulta la comparación de la tasa de crecimiento de los beneficios con su media de 5 años.

Beneficios vs. Industria: A039840 ha pasado a ser rentable en el último año, lo que hace difícil comparar el crecimiento de sus beneficios en el último año con el del sector Medical Equipment (-4%).

Rentabilidad financiera

Alta ROE: El Retorno sobre el capital de A039840 (1.3%) se considera bajo.

Rentabilidad económica

Rendimiento del capital invertido

Descubre empresas con buenos resultados en el pasado

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

DIO Resultados de beneficios anteriores

Pasado controles de criterios 2/6

Información clave

Actualizaciones de resultados anteriores recientes

Full year 2023 earnings released: EPS: ₩227 (vs ₩1,380 loss in FY 2022)

Full year 2022 earnings: EPS and revenues miss analyst expectations

Third quarter 2021 earnings released: EPS ₩602 (vs ₩232 in 3Q 2020)

Third quarter 2021 earnings released: EPS ₩602 (vs ₩232 in 3Q 2020)

First quarter 2021 earnings released: EPS ₩704 (vs ₩349 in 1Q 2020)

Full year 2020 earnings released: EPS ₩758 (vs ₩1,483 in FY 2019)

Recent updates

Full year 2023 earnings released: EPS: ₩227 (vs ₩1,380 loss in FY 2022)

New major risk - Revenue and earnings growth

DIO Corporation announced that it expects to receive KRW 85 billion in funding from H Private Equity Co., Ltd.

DIO Corporation announced that it expects to receive KRW 85 billion in funding from H Private Equity Co., Ltd.

Price target decreased by 10% to ₩38,200

Now 24% undervalued after recent price drop

Now 21% undervalued after recent price drop

Full year 2022 earnings: EPS and revenues miss analyst expectations

Investor sentiment improved over the past week

Less than half of directors are independent

DIO Corporation (KOSDAQ:A039840) announces an Equity Buyback for KRW 3,000 million worth of its shares.

Consensus revenue estimates fall by 12%

Investor sentiment deteriorated over the past week

Price target decreased to ₩53,500

Less than half of directors are independent

Price target decreased to ₩54,200

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS ₩602 (vs ₩232 in 3Q 2020)

Third quarter 2021 earnings released: EPS ₩602 (vs ₩232 in 3Q 2020)

Price target increased to ₩58,200

Investor sentiment improved over the past week

First quarter 2021 earnings released: EPS ₩704 (vs ₩349 in 1Q 2020)

We Think DIO (KOSDAQ:039840) Can Stay On Top Of Its Debt

Consensus forecasts updated

An Intrinsic Calculation For DIO Corporation (KOSDAQ:039840) Suggests It's 43% Undervalued

What Type Of Shareholders Make Up DIO Corporation's (KOSDAQ:039840) Share Registry?

Full year 2020 earnings released: EPS ₩758 (vs ₩1,483 in FY 2019)

Has DIO (KOSDAQ:039840) Got What It Takes To Become A Multi-Bagger?

New 90-day high: ₩40,650

What Does DIO Corporation's (KOSDAQ:039840) Share Price Indicate?

Price target raised to ₩43,500

Investor sentiment improved over the past week

New 90-day high: ₩35,250

DIO (KOSDAQ:039840) Seems To Use Debt Quite Sensibly

How Much Did DIO's(KOSDAQ:039840) Shareholders Earn From Share Price Movements Over The Last Year?

New 90-day high: ₩33,850

Is DIO Corporation's (KOSDAQ:039840) Stock Price Struggling As A Result Of Its Mixed Financials?

Should You Use DIO's (KOSDAQ:039840) Statutory Earnings To Analyse It?

Do Institutions Own DIO Corporation (KOSDAQ:039840) Shares?

Analysts lower EPS estimates to ₩1,346

New 90-day high: ₩32,950

Third quarter 2020 earnings released: EPS ₩232

New 90-day high: ₩31,550

New 90-day high: ₩29,800

Price target lowered to ₩32,438

Desglose de ingresos y gastosBeta

Historial de beneficios e ingresos

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Rentabilidad financiera

Rentabilidad económica

Rendimiento del capital invertido

Descubre empresas con buenos resultados en el pasado

Desglose de ingresos y gastos
Beta